Skip to content
‹ Back to IndustriesSciences

What is the Key to Sustainability in the Final Frontier?

On the Space to Grow podcast, Astroscale's Chris Blackerby and Charity Weeden discuss the technology, international policy, and scalability required for sustainable space exploration. They draw on experience spanning civil, commercial, and defense sectors to address the next generation of space sustainability challenges, including orbital debris and responsible use of space.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · AstroscaleCharity WeedenChris BlackerbyInternational
Share

Key takeaways

01

Sustainability in space requires coordination across civil, commercial, and defense sectors.

02

International policy frameworks are critical to governing debris removal and orbital resource management.

03

Scalable technology solutions are essential for the long-term viability of space operations.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

There are three distinct areas of space exploration—civil, commercial, and defense. It’s rare to find a leader that has contributed to all three. Space to Grow welcomed such a pioneer, Pamela Melroy. Melroy spoke with hosts Chris Blackerby and Charity Weeden about her career and the importance of all three aspects cooperating.

Melroy has an impressive career. She was an astronaut, flying three times, and was commander of one of those missions. She held other positions at NASA, the FAA, DARPA, and Lockheed Martin. Now she’s the Director of Space Technology and Policy for Nova Systems, an engineering and technology solutions partner.

Melroy described her career path. “I wanted to be an astronaut and didn’t outgrow it. I had a singular focus on it.

“Sustainability is a national problem, and cooperation essential. The International Space Station represents this. It requires trust to go forward.” – Pam Melroy

Then it was time to stop flying, and I wanted to keep working on important things and another mountain to climb.” It became mountains as she traversed through all aspects of the space world, learning and adapting along the way.

Her experience taught her that the three areas of space were in deep silos. Each has different agendas, motivations, and priorities. Those don’t always align, even for many fundamental areas. She noted the example of servicing satellites. “NASA knows all about it, and I did it in space. However, there’s a fundamentally different approach to the problem.”

Additionally, there is the complex problem of space debris removal, requiring international collaboration, but it’s not happening. Melroy said, “It’s easy to point the finger at the policy issue as holding us back. Sustainability is a national problem, and cooperation essential. The International Space Station represents this. It requires trust to go forward.”

Listen to Previous Episodes Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic is buying Lantheus' contract manufacturing unit and Springfield, New Jersey radiopharmaceutical plant, plus a long-term deal to make lutetium Lu 177 dotatate for Lantheus. Radioligand developers looking for capacity should ask how much of the plant's capacity is still open.

  • 01A long-term supply contract attached to a plant sale could help keep costly hot-cell capacity in use. According to Grand View Research, committed supply agreements are among the tools that help providers align capital spending with customer development milestones.
  • 02Radioligand developers evaluating PharmaLogic's Agilera unit should ask how much Springfield capacity the lutetium Lu 177 dotatate contract will take up and how much is left for new programs.
  • 03Two pending transactions shape what to watch next: regulatory review and closing conditions for the PharmaLogic purchase, and Curium’s August offer of upward of $8 billion for Lantheus, which is still closing.

Nov 18, 2026

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA agreed to buy Rapid Micro Biosystems, maker of the Growth Direct microbial testing platform, for $0.75 per share in cash. The deal turns a 2025 distribution partnership into ownership. Growth Direct instruments, consumables and software would then come from the company that already sells QC products to pharma labs, pending a December 2026 close.

  • 01Growth Direct shifts from a Merck-distributed product, under a February 2025 agreement, to a Merck-owned one inside a QC portfolio that spans environmental monitoring, in-process and release testing.
  • 02For labs that already run Growth Direct alongside MilliporeSigma QC products, the useful question is how the platform's digital sample records will connect to the rest of that workflow after close.
  • 03The next date to watch is the Schedule TO filing that opens the tender offer; closing targeted for December 2026 requires a majority of Rapid Micro’s voting shares to be tendered.

Nov 17, 2026

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, the programme logged 133 follow-up visits against 17 treatments; with roughly 15 years of twice-yearly checkups per patient, the follow-up load is likely to keep growing even if new treatments stay flat.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03A practical question for gene therapy services: who alerts the lab when a child’s fever delays a blood draw? At SR-Tiget, research nurses manage the patient schedule and coordinate sample timing with the lab.

Nov 16, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

CB
Chris Blackerby

Group COO at Astroscale

Chris Blackerby is Group COO at Astroscale, a leading company focused on satellite servicing and orbital sustainability. He previously served as NASA's Attache to Asia, giving him rare experience across civil, commercial, and defense space sectors. He is a recognized voice on space debris removal, international space policy, and the future of sustainable space exploration.

CW
Charity Weeden

Vice President, Global Space Policy

Astroscale

Charity Weeden serves as Vice President of Global Space Policy at Astroscale, where she focuses on advancing international regulatory frameworks and norms for responsible space operations. She brings extensive experience in space policy from prior roles in government and industry.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512